Bridging gaps in MSC therapy development through strategic partnership
Now available to watch on demand
Learn how strategic collaboration helps close development gaps and advance standardized MSC therapies toward clinical translation.
Advancing mesenchymal stromal cell therapies requires addressing critical challenges in achieving consistency in starting material, manufacturing inputs and development strategies. The inherent ariability in donor sources, isolation methods and culture conditions often leads to heterogeneity, which can hinder reproducibility and slow the translational process from research to clinical application.
Addressing these challenges increasingly requires collaboration across the therapy ecosystem. In this discussion, Lindsay Davies from NextCell Pharma (Stockholm, Sweden) will explore how strategic partnerships can play a pivotal role in tackling these issues. By aligning MSC sources with scalable culture media and establishing reliable supply chains, collaborative approaches can support standardized research workflows, mitigate development risks, and accelerate the journey from discovery to clinical translation.
Can’t see the form below? Register for the webinar here.
What will you learn?
- Identify sources of variability impacting MSC research and development
- Evaluate how strategic collaborations can help close the gaps across MSC development
- Assess the role of standardized MSC starting materials in improving experimental reproducibility
- Recognize how ecosystem partnerships support scalable manufacturing and translational progress
Who this may interest?
- Scientists and developers specializing in MSC therapies, including early-stage research and clinical applications
- Process development leaders focused on improving MSC manufacturing consistency and scalability
- Investigators studying MSC biology, mechanisms and therapeutic potential
- D30Innovation leaders and industry professionals exploring strategic partnerships to advance MSC therapies and streamline supply chains
Lindsay Davies
Chief Scientific Officer
NextCell Pharma (Stockholm, Sweden)
Lindsay Davies completed her PhD in 2006 at Cardiff University (UK). Focussing on cell therapy for cartilage repair, with a career in advanced therapies spanning over 20 years across Europe. In 2020, Dr Davies moved into industry setting up her own consulting company, CellTherEx (Stockholm, Sweden) supporting the advanced therapy space before also joining NextCell Pharma, a clinical stage stromal cell therapy company as their Chief Scientific Officer. In 2024, Dr Davies co-founded and launched QVance (Stockholm, Sweden), a quality control analytics service provider for advanced therapy developers, where she is CEO in addition to her continued CSO role at NextCell.
Today Lindsay is a well-recognised KOL in the ATMP community, recently elected as Vice President Elect for Europe at the ISCT, sitting on their European Task Force and several committees related to process development and commercialisation, as well as the inaugural Chair for ISCT’s European Industry committee. She is also an industry representative for the Swedish national ATMP coordinating team and Board member for a number of national and international entities.
This fireside chat was recorded on 14 April 2026.
In association with FUJIFILM Biosciences.
